Universite Paris Cité, Département de Médecine Générale, F-75006, Paris, France
Université Sorbonne Paris Nord, Département Universitaire de Médecine Générale, DUMG, F-93430, Villetaneuse, France.
BMJ Open. 2022 Mar 15;12(3):e058879. doi: 10.1136/bmjopen-2021-058879.
Breast cancer screening decision aids (DAs) are designed to help women decide whether or not to participate in mammography-based programmes. We aimed to explore women's and healthcare professionals' expectations of a breast cancer screening DA, as part of the French DEDICACES study.
This French qualitative study was based on semistructured, individual interviews with women from the general population, general practitioners (GPs), midwives, gynaecologists, radiologists and screening centre managers. Sampling was purposive and used diversification criteria. The inductive analysis was based on grounded theory.
Between April 2018 and May 2019, we interviewed 40 people: 13 women, 14 GPs, 4 gynaecologists, 3 midwives, 3 radiologists and 3 screening centre managers. The women and the healthcare professionals considered that a DA could help to improve levels of knowledge, harmonise medical practice and provide reliable, comprehensive information. Overall, the interviewees wanted an easy-to-use, intuitive, graphic-rich, interactive, computer-based, patient-centred DA. Use of the DA might be limited by a lack of familiarity with shared decision-making (SDM), the risk of misuse and a preference for asymmetric positive information.
The present results are likely to facilitate the development of the first validated tool for SDM support in French breast cancer screening programmes.
乳腺癌筛查决策辅助工具（DA）旨在帮助女性决定是否参与基于乳房 X 光摄影的项目。我们旨在探索女性和医疗保健专业人员对乳腺癌筛查 DA 的期望，这是法国 DEDICACES 研究的一部分。
这项法国定性研究基于对普通人群中的女性、全科医生（GP）、助产士、妇科医生、放射科医生和筛查中心经理的半结构化个体访谈。抽样是有目的的，并使用多样化标准。归纳分析基于扎根理论。
2018 年 4 月至 2019 年 5 月，我们采访了 40 人：13 名女性、14 名全科医生、4 名妇科医生、3 名助产士、3 名放射科医生和 3 名筛查中心经理。女性和医疗保健专业人员认为，DA 可以帮助提高知识水平、协调医疗实践并提供可靠、全面的信息。总体而言，受访者希望使用易于使用、直观、图形丰富、互动、基于计算机、以患者为中心的 DA。DA 的使用可能会受到对共享决策（SDM）缺乏熟悉程度、误用风险和对不对称正信息的偏好的限制。
目前的结果可能有助于为法国乳腺癌筛查项目中的 SDM 支持开发第一个经过验证的工具。
